RAPP (Rapport Therapeutics) Revenue: $20.00 Mil (TTM As of Mar. 2026)


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Revenue?

Rapport Therapeutics RAPP -0.60% 14 Revenue is $20.00 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Rapport Therapeutics's revenue for the three months ended in Mar. 2026 was $20.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $20.00 Mil. Rapport Therapeutics's Revenue per Share for the three months ended in Mar. 2026 was $0.42. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.42.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Rapport Therapeutics  (NAS:RAPP) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Rapport Therapeutics Revenue Related Terms

Rapport Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Revenue Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Revenue
0.00 0.00 0.00 0.00

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 20.00

RAPP vs SION, TYRA, IOVA: Revenue Comparison

For the Biotechnology subindustry, Rapport Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapport Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Rapport Therapeutics's Revenue falls into.


RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $20.00 Mil mean?
Rapport Therapeutics (RAPP) has a Revenue of $20.00 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Revenue too high?
Rapport Therapeutics' current Revenue is $20.00 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Revenue compare to SION and TYRA?
Rapport Therapeutics' Revenue of $20.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current Revenue is $20.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Revenue of $20.00 Mil. The current Revenue is $20.00 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Revenue is $20.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price